Lymph node metastasis to predict overall survival in oligometastatic prostate cancer in Asian patients.

Authors

null

Junryo Rii

Department of Urology Graduate School of Medicine, Chiba University, Chiba, Japan

Junryo Rii , Shinichi Sakamoto , Yasutaka Yamada , Yusuke Imamura , Kazuyoshi Nakamura , Akira Komiya , Hiroomi Nakatsu , Tomohiko Ichikawa

Organizations

Department of Urology Graduate School of Medicine, Chiba University, Chiba, Japan, Chiba University Graduate School of Medicine, Chiba-Shi, Japan, Chiba University Graduate School of Medicine, Chiba, Japan, Department of Gastroenterology, Chiba Cancer Center, Chiba, Japan, Asahi General Hospital, Asahi, Japan, Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan

Research Funding

No funding received
None

Background: The oligometastatic cancer has been suggested as an intermediate state between localized disease and wide range metastases. Clinical significance of local treatment in oligometastatic prostate cancer (PCa) has been a recent topic. However, due to racial differences, there are no standard definitions of oligometastasis, especially in Asians. Here we studied the risk factor among Japanese oligometastatic PCa patients. Methods: We retrospectively analyzed the medical record of 207 patients, including locally advanced (T3 or T4N0M0), lymph-node-positive (N1), and ≤10 bone metastases cancer. All patients received androgen deprivation therapy only. The number of bone metastasis and clinical factors were evaluated in association with OS. Results: Median age, PSA at baseline and OS were 73 years, 48.8ng/ml and 121 months respectively. The cutoff value for the number of bone metastases that have the greatest impact on OS was ≥2 (HR 3.05, p = 0.0001), followed by ≥7 (HR 3.03, p = 0.0005). In multivariate analysis, lymph node metastasis (HR 2.54, p = 0.003) and ≥2 bone metastases (HR 2.67, p = 0.009) were independent predictors of OS. In risk classification based on independent predictors, OS was significantly classified in High (3-4 factors), Intermediate (1-2 factors), and Low (no factor) risk groups (p <0.0001). Furthermore, even among same risk factors group, inclusion of lymph node metastasis significantly increased the HR by 2.34 (p = 0.039). Conclusions: Not only the number of bone metastasis but also lymph node metastasis predict OS of oligometastatic PCa patients.

Univariate and Multivariate analyses of factors associated with OS.

CharacteristicCut offUnivariate analysis
Multivariate analysis
HRLower 95%Upper 95%P valueHRLower 95%Upper 95%P value
Age≥73y1.300.732.280.36----
PSA≥ 48.8 ng/mL1.100.621.910.74----
Hb≤ 13.8 g/dL1.440.822.550.20----
Alb≤4.3 g/dL1.740.973.210.061----
Alkaline phosphatase≥251 IU/L2.341.284.530.0051.690.903.380.11
Gleason score≥82.291.105.600.0271.310.493.770.60
Lymph node metastasis+/-3.221.845.760.00032.541.344.990.003
Visceral metastasis+/-1.010.242.760.98----
Bone metastasis
number
≥23.051.725.620.00012.671.166.000.009

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2020 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers

Track

Urothelial Carcinoma,Adrenal Cancer,Penile Cancer,Prostate Cancer - Advanced,Prostate Cancer - Localized,Testicular Cancer,Urethral Cancer

Sub Track

Therapeutics

Citation

J Clin Oncol 38, 2020 (suppl 6; abstr 237)

Abstract #

237

Poster Bd #

B15

Abstract Disclosures

Similar Abstracts

Abstract

2023 ASCO Annual Meeting

The incidence and risk factors predictive of bone metastases at initial diagnosis of malignancy.

First Author: Brendan Knapp

Abstract

2024 ASCO Genitourinary Cancers Symposium

Predictors of PSMA positivity at initial staging of prostate cancer.

First Author: Eric Li

Abstract

2023 ASCO Genitourinary Cancers Symposium

Characterization of lymph node metastases in prostate cancer.

First Author: Josh Gottlieb